| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 69.36 mm | 69.36 mm | 69.36 mm | 69.36 mm | 69.36 mm | 69.36 mm |
| Cash burn (monthly) | (no burn) | 1.25 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 5.69 mm | n/a | n/a | n/a | n/a |
| Cash remaining | n/a | 63.67 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 50.8 | n/a | n/a | n/a | n/a |
| 13F holders | Current |
|---|---|
| Total holders | 104 |
| Opened positions | 18 |
| Closed positions | 17 |
| Increased positions | 33 |
| Reduced positions | 23 |
| 13F shares | Current |
|---|---|
| Total value | 70.20 bn |
| Total shares | 35.61 mm |
| Total puts | 16.30 k |
| Total calls | 50.60 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| BlackRock | 3.83 mm | $9.76 bn |
| Vanguard | 3.64 mm | $9.27 bn |
| Frazier Life Sciences Management | 3.06 mm | $7.81 bn |
| Millennium Management | 2.88 mm | $7.35 bn |
| Integrated Core Strategies | 2.00 mm | $7.22 mm |
| Acadian Asset Management | 1.97 mm | $5.02 mm |
| Renaissance Technologies | 1.77 mm | $4.52 bn |
| Acorn Bioventures | 1.70 mm | $0.00 |
| Frazier Life Sciences Public Fund | 1.30 mm | $7.24 mm |
| Eversept Partners | 1.29 mm | $3.30 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Feb 25 | Auerbach Alan H | Common Stock | Grant | Acquire A | No | No | 0 | 198,399 | 0.00 | 7,228,073 |
| 7 Feb 25 | Auerbach Alan H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.78 | 274,622 | 763.45 k | 274,622 |
| 7 Feb 25 | Douglas M Hunt | Common Stock | Grant | Acquire A | No | No | 0 | 48,117 | 0.00 | 172,711 |
| 7 Feb 25 | Douglas M Hunt | Stock Option Common Stock | Grant | Acquire A | No | No | 2.78 | 66,604 | 185.16 k | 66,604 |
| 7 Feb 25 | Jeffrey Jerome Ludwig | Common Stock | Grant | Acquire A | No | No | 0 | 47,841 | 0.00 | 156,792 |
| 7 Feb 25 | Jeffrey Jerome Ludwig | Stock Option Common Stock | Grant | Acquire A | No | No | 2.78 | 66,221 | 184.09 k | 66,221 |
| 7 Feb 25 | Maximo F Nougues | Common Stock | Grant | Acquire A | No | No | 0 | 61,456 | 0.00 | 213,751 |
| 7 Feb 25 | Maximo F Nougues | Stock Option Common Stock | Grant | Acquire A | No | No | 2.78 | 85,067 | 236.49 k | 85,067 |
| 2 Jan 25 | Auerbach Alan H | Common Stock | Sell | Dispose S | No | Yes | 3.1517 | 33,841 | 106.66 k | 7,029,674 |
